Brief: Absci Announces Positive Interim Phase 1 Data From The Headline™ Trial Of Abs-201, A Novel Antibody Targeting The Prolactin Receptor (Prlr)
BRIEF-Absci Announces Positive Interim Phase 1 Data From The Headline™ Trial Of Abs-201, A Novel Antibody Targeting The Prolactin Receptor (Prlr) June 24 (Reuters) - Absci Corp ABSI.O:
ABSCI ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FROM THE HEADLINE™ TRIAL OF ABS-201, A NOVEL ANTIBODY TARGETING THE PROLACTIN RECEPTOR (PRLR)
ABSCI CORP - ABS-201 WELL TOLERATED WITH FAVORABLE SAFETY DATA IN ALL SAD COHORTS
ABSCI CORP - NO SERIOUS ADVERSE EVENTS REPORTED IN ABS-201 PHASE 1 INTERIM DATA
ABSCI CORP - INTERIM PROOF-OF-CONCEPT DATA FOR ABS-201 EXPECTED IN SECOND HALF OF 2026
ABSCI CORP - FIRST MULTIPLE ASCENDING DOSE COHORT OF ABS-201 INITIATED IN AGA PARTICIPANTS
ABSCI CORP - ABS-201 HALF-LIFE ESTIMATED AT LEAST 65 DAYS SUPPORTS INFREQUENT DOSING
ABSCI CORP: FULL PROOF-OF-CONCEPT DATA ANTICIPATED IN EARLY 2027
Source text: ID:nGNX2BgzPK
Further company coverage: ABSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave